

Agata Bielecka-Dabrowa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/797474/publications.pdf>

Version: 2024-02-01

49
papers

1,045
citations

394286

19
h-index

434063

31
g-index

51
all docs

51
docs citations

51
times ranked

1731
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice. <i>Irish Journal of Medical Science</i> , 2022, 191, 213-227. | 0.8 | 6 |
| 2 | Cardiac manifestations of COVID-19. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 365. | 0.5 | 19 |
| 3 | Prognostic value of left atrial volume index in acute coronary syndrome: A systematic review and meta-analysis. <i>Clinical Physiology and Functional Imaging</i> , 2021, 41, 128-135. | 0.5 | 5 |
| 4 | Left Ventricular Diastolic Dysfunction as Predictor of Unfavorable Prognosis After ESUS. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 617-627. | 1.1 | 2 |
| 5 | Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications. <i>ESC Heart Failure</i> , 2021, 8, 2397-2418. | 1.4 | 18 |
| 6 | Factors and Prognostic Significance of Impaired Exercise Tolerance in Women over 40 with Arterial Hypertension. <i>Journal of Personalized Medicine</i> , 2021, 11, 759. | 1.1 | 1 |
| 7 | Patient after correction Taussig-Bing anomaly with severe neo-aortic regurgitation after sudden cardiac arrest. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e05085. | 0.2 | 0 |
| 8 | Find the Essence through the Phenomena: Cardiovascular Diseases and Biomarkers 2019. <i>Disease Markers</i> , 2020, 2020, 1-2. | 0.6 | 1 |
| 9 | Cardioprotective properties of leptin in patients with excessive body mass. <i>Irish Journal of Medical Science</i> , 2020, 189, 1259-1265. | 0.8 | 6 |
| 10 | Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). <i>Nutrition Research Reviews</i> , 2020, 33, 155-179. | 2.1 | 31 |
| 11 | Pharmacological management of malignant hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1189-1192. | 0.9 | 4 |
| 12 | Treating mild hypertension in young adults: is pharmacotherapy necessary?. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1115-1118. | 0.9 | 1 |
| 13 | The Role of Adipokines in the Development of Arterial Stiffness and Hypertension. <i>Angiology</i> , 2020, 71, 754-761. | 0.8 | 15 |
| 14 | The outcomes of hypertension treatment depending on gender in patients over 40 years of age. <i>Przegląd Menopauzalny</i> , 2020, 19, 174-178. | 0.6 | 2 |
| 15 | Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function. <i>Clinical Research in Cardiology</i> , 2019, 108, 225-233. | 1.5 | 35 |
| 16 | The potential role of inflammation in cryptogenic stroke. <i>Advances in Medical Sciences</i> , 2019, 64, 381-387. | 0.9 | 8 |
| 17 | Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. <i>Lipids in Health and Disease</i> , 2019, 18, 188. | 1.2 | 31 |
| 18 | Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology. <i>Disease Markers</i> , 2019, 2019, 1-10. | 0.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Cytisine - From the Past to the Future. <i>Current Pharmaceutical Design</i> , 2019, 24, 4413-4423. | 0.9 | 13 |
| 20 | Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke. <i>Cardiology Journal</i> , 2019, 26, 438-450. | 0.5 | 6 |
| 21 | Proscaropenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 331-353. | 4.0 | 20 |
| 22 | Novel drugs for heart rate control in heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 517-525. | 1.7 | 8 |
| 23 | Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. <i>Archives of Medical Science</i> , 2018, 14, 890-909. | 0.4 | 42 |
| 24 | Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?. <i>Current Heart Failure Reports</i> , 2018, 15, 224-238. | 1.3 | 14 |
| 25 | The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. <i>Scientific Reports</i> , 2017, 7, 8974. | 1.6 | 12 |
| 26 | Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies. <i>International Journal of Cardiology</i> , 2016, 221, 1073-1080. | 0.8 | 33 |
| 27 | Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension. <i>Scientific Reports</i> , 2015, 5, 8916. | 1.6 | 27 |
| 28 | The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension. <i>International Journal of Molecular Sciences</i> , 2015, 16, 10715-10733. | 1.8 | 33 |
| 29 | The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy â€” 5-year follow-up. <i>Lipids in Health and Disease</i> , 2013, 12, 47. | 1.2 | 25 |
| 30 | The effects of statins on blood pressure in normotensive or hypertensive subjects â€” A meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 168, 2816-2824. | 0.8 | 37 |
| 31 | Heart failure biomarkers in patients with dilated cardiomyopathy. <i>International Journal of Cardiology</i> , 2013, 168, 2404-2410. | 0.8 | 43 |
| 32 | Is Percutaneous Transluminal Coronary Angioplasty the Treatment of Choice for Iatrogenic Stenosis of the Left Main Coronary Artery following Aortic Valve Replacement?. <i>Heart Surgery Forum</i> , 2013, 16, 190. | 0.2 | 0 |
| 33 | An update on biomarkers of heart failure in hypertensive patients. <i>Journal of Hypertension</i> , 2012, 30, 1681-1689. | 0.3 | 51 |
| 34 | The meaning of hypokalemia in heart failure. <i>International Journal of Cardiology</i> , 2012, 158, 12-17. | 0.8 | 55 |
| 35 | Biological artificial valve dysfunction â€” single-centre, observational echocardiographic study in patients operated on before age 65 years. <i>Archives of Medical Science</i> , 2011, 6, 993-999. | 0.4 | 5 |
| 36 | Redo surgery risk in patients with cardiac prosthetic valve dysfunction. <i>Archives of Medical Science</i> , 2011, 2, 271-277. | 0.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Malignancy-Associated Dyslipidemia. <i>Open Cardiovascular Medicine Journal</i> , 2011, 5, 35-40. | 0.6 | 46 |
| 38 | What is the risk of hyperkalaemia in heart failure?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2329-2338. | 0.9 | 8 |
| 39 | The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. <i>Current Cardiovascular Risk Reports</i> , 2011, 5, 174-179. | 0.8 | 46 |
| 40 | Statins and dilated cardiomyopathy: do we have enough data?. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 315-323. | 1.9 | 18 |
| 41 | Sources of Thromboembolism in Patients with Correctly Functioning Mechanical Valves: A Single-Center Transesophageal Echocardiographic Study. <i>Heart Surgery Forum</i> , 2011, 14, 149. | 0.2 | 0 |
| 42 | Current Place of Beta-Blockers in the Treatment of Hypertension. <i>Current Vascular Pharmacology</i> , 2010, 8, 733-741. | 0.8 | 23 |
| 43 | Takotsubo cardiomyopathy – The current state of knowledge. <i>International Journal of Cardiology</i> , 2010, 142, 120-125. | 0.8 | 78 |
| 44 | Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study. <i>Lipids in Health and Disease</i> , 2010, 9, 21. | 1.2 | 10 |
| 45 | The mechanisms of atrial fibrillation in hyperthyroidism. <i>Thyroid Research</i> , 2009, 2, 4. | 0.7 | 85 |
| 46 | HSP 70 and atherosclerosis – protector or activator?. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 307-317. | 1.5 | 46 |
| 47 | The meaning of early percutaneous coronary intervention in acute coronary syndrome with preserved ST elevation. <i>Open Medicine (Poland)</i> , 2009, 4, 265-271. | 0.6 | 2 |
| 48 | The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy. <i>Medical Science Monitor</i> , 2009, 15, MS12-23. | 0.5 | 36 |
| 49 | New methods in laboratory diagnostics of dilated cardiomyopathy. <i>Cardiology Journal</i> , 2008, 15, 388-95. | 0.5 | 12 |